Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.53 |
| ▸ | MMP14 | P50281 | 5/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862196 | 0.93 | MMP2 (0.61) | MMP2MMP14POLBMMP7DYRK1A | |
| SCHEMBL862370 | 0.93 | MMP2 (0.61) | MMP2MMP14POLBDYRK1A | |
| SCHEMBL5359695 | 0.89 | CYP3A4 (0.59) | — | |
| SCHEMBL862189 | 0.89 | CYP3A4 (0.59) | — | |
| SCHEMBL1974812 | 0.87 | BACE1 (0.62) | PTPN1POLBALOX5 | |
| SCHEMBL862110 | 0.87 | BACE1 (0.62) | PTPN1POLBALOX5 | |
| SCHEMBL3805652 | 0.82 | CYP3A4 (0.59) | MMP2MMP14 | |
| SCHEMBL862116 | 0.82 | MMP2 (0.57) | MMP2MMP14POLBMMP7DYRK1A | |
| Meciadanol SCHEMBL862417 | 0.81 | BACE1 (0.68) | MMP2MMP14POLBDYRK1A | |
| Meciadanol SCHEMBL790769 | 0.81 | BACE1 (0.68) | MMP2MMP14POLBDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143308-B2 | Synthesis of oligo/poly(catechins) and methods of use | UNIVERSITY OF MASSACHUSETTS LOWELL (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090170928-A1 | Synthesis of oligo/poly(catechins) and methods of use | GOVERNMENT OF THE UNITED STATES | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170928-A1 | Synthesis of oligo/poly(catechins) and methods of use | POLI, PUF60, FABP3 | MMP2 254/4885MMP14 52/4885PTPN1 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.